Xoma Corp. said Tuesday that it has been named in fiveadditional shareholders lawsuits, bringing to seven the numberof suits against the Berkeley, Calif.-based company. The firsttwo suits were filed on July 24. The suits allege that thecompany and key executives, in their race to get marketingapproval for Xoma's E5 gram-negative sepsis product ahead ofCentocor Inc., misled investors about the prospects for Foodand Drug Administration approval. Xoma expects all the suitsto be consolidated into one action. E5 is scheduled to bereviewed by a Food and Drug Administration advisorycommittee on Sept. 4. Xoma stock (NASDAQ:XOMA) closed at$16.75 on Tuesday, up 25 cents.

(c) 1997 American Health Consultants. All rights reserved.